OTC Watch

All stocks / PURE

PURE BIOSCIENCE, INC. PURE

PURE Bioscience (PURE): shares outstanding up 25% in a year and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated float OTCQBCalifornia, USA
Live quote on OTC Markets

Market listing

Full name
PURE BIOSCIENCE
Market tier
OTCQB
Trading status
Active
Last trade
09:30:01
Website
www.purebio.com/
Source: Stockwatch, 2026-11-17

News headlines

PURE Bioscience Reports Fiscal 2026 Financial Results
2026-10-29 16:05 · News Release
PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results
2026-06-15 16:05 · News Release
PURE Bioscience Reports Fiscal Second Quarter 2026 Financial Results
2026-03-16 16:05 · News Release
PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results
2025-12-15 16:05 · News Release
PURE Bioscience, Inc. Announces Leadership Promotions
2025-11-19 16:05 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2026-07-31
The report says
Revenue
$2,318,000
Net loss
($2,483,000)
What it means

It spends more than it earns

Under strain

Customers paid it $2.3 million in the year. It lost $2.5 million. For every $1 that came in, about $2.07 went out.

The report says
Cash and cash equivalents
$569,000
Net cash used in operating activities
($1,738,000)
What it means

The cash could run out soon

Under strain

It had $569,000 in the bank and used about $144,833 a month. At that pace the money lasts about 4 months unless it borrows or sells more shares.

The report says
Total assets
$1,193,000
Total liabilities
$7,592,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $1.2 million. Its debts and unpaid bills add up to $7.6 million. That is about $6.36 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-10-29

Shares outstanding rose from 111,886,473 (2025-10-29) to 140,201,055 (2026-10-29), up 25%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-10-29

Estimated float about 140,201,055 shares as of 2026-10-29: 140,201,055 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-10-31
111.9M
2025-12-15
111.9M
2026-01-31
111.9M
2026-03-16
111.9M
2026-04-30
130.0M
2026-06-15
130.0M
2026-07-31
130.0M
2026-10-29
140.2M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-10-29 8-K8-K
2026-10-29 10-K10-K
2026-10-20 8-K8-K
2026-06-15 8-K8-K
2026-06-15 10-Q10-Q
2026-05-05 8-K8-K
2026-03-17 8-K8-K
2026-03-17 10-Q10-Q
2026-02-20 8-K8-K
2025-12-30 DEF 14ADEF 14A
2025-12-18 PRE 14APRE 14A
2025-12-15 8-K8-K

Common questions about PURE

Does PURE file reports with the SEC?

Yes. PURE Bioscience files with the SEC under company number 0001006028. The most recent filing we hold is a 8-K dated 2026-10-29.

Source record

How many PURE shares are outstanding?

140,201,055 shares as of 2026-10-29, as reported to the SEC. That is up 25% from 111,886,473 on 2025-10-29.

Source record

Has PURE filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs PURE Bioscience?

Officers named in its insider filings: Jeffrey Scott Kitchell (President, Corporate Secretary).

Source record

Is PURE Bioscience making money?

Customers paid it $2.3 million in the year. It lost $2.5 million. For every $1 that came in, about $2.07 went out. (Annual figures to 2026-07-31. Facts from the company's own report, not a recommendation.)

Source record